Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle

BioEssays

Volumn 29, Issue 10, 2007, Pages 1029-1038

  Beaulieu, Lea M ^a   Whitley, Brandi R ^a   Wiesner, Theodore F ^b,d   Rehault, Sophie M ^a   Palmieri, Diane ^a,e   Elkahloun, Abdel G ^c,f   Church, Frank C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d CATO RESEARCH LTD   (United States)

^e STATION DE RECHERCHES AVICOLES   (France)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; UROKINASE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TRANSFER; HUMAN; HYPERINSULINEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MICROENVIRONMENT; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RISK FACTORS; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 34948856941     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20640     Document Type: Review

References (100)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. 2007. Cancer statistics, 2007. CA Cancer J Clin 57:43-66.
2. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M. 2006. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183.
3. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, et al. 2002. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116-128.
4. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, et al. 2000. The urokinase system of plasminogen activation and prognosis in 780 breast cancer patients. Cancer Research 60:636-643.
5. Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet 365:1415-1428.
6. Despres JP, Lemieux I. 2006. Abdominal obesity and metabolic syndrome. Nature 444:881-887.
7. Rose DP, Komninou D, Stephenson GD. 2004. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153-165.
8. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. 2005. Diabetes mellitus and breast cancer. Lancet Oncol 6:103-111.
9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638.
10. Duncan AM. 2004. The role of nutrition in the prevention of breast cancer. AACN Clin Issues 15:119-135.
11. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. 2003. Are imprecise methods obscuring a relation between fat and breast cancer? Lancet 362:212-214.
12. Kroenke CH, Chen WY, Rosner B, Holmes MD. 2005. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23:1370-1378.
13. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, et al. 2005. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 14:33-40.
14. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. 2004. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 96:1152-1160.
15. Atkinson SJ, English JL, Holway N, Murphy G. 2004. Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells. FEBS Lett 566:65-70.
16. Bray GA. 2004. Medical consequences of obesity. J Clin Endocrinol Metab 89:2583-2589.
17. Hsueh WA, Lyon CJ, Quinones MJ. 2004. Insulin resistance and the endothelium. Am J Med 117:109-117.
18. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, et al. 2003. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9:5699-5704.
19. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. 2005. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115:959-968.
20. Ronti T, Lupattelli G, Mannarino E. 2006. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64:355-365.
21. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. 2006. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond).
22. Griffiths SL, Grainger DJ. 2006. Proposal of a novel diabetogenic mechanism involving the serpin PAI-1. Bioessays 28:629-641.
23. Alessi MC, Juhan-Vague I. 2006. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26:2200-2207.
24. Stefansson S, Lawrence DA. 2003. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE 189:pe24.
25. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, et al. 2004. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 91:438-449.
26. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, et al. 2005. Plasminogen activation and cancer. Thromb Haemost 93:676-681.
27. Dellas C, Loskutoff DJ. 2005. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93:631-640.
28. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, et al. 2001. Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93:913-920.
29. Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, et al. 2006. An overview of the serpin superfamily. Genome Biol 7:216.
30. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, et al. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276:33293-33296.
31. Liu G, Shuman MA, Cohen RL. 1995. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60:501-506.
32. Hekman CM, Loskutoff DJ. 1985. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581-11587.
33. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, et al. 1988. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454-15461.
34. Mimuro J, Sawdey M, Hattori M, Luskutoff DJ. 1989. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1), Nucleic Acids Res 17:8872.
35. Stefansson S, Muhammad S, Cheng XF, Battey FD, Strickland DK, Lawrence DA. 1998. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem 273:6358-6366.
36. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, et al. 1997. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. Embo J 16:2610-2620.
37. DeClerck YA, Imren S. 1994. Protease inhibitors: Role and potential therapeutic use in human cancer. European J Cancer 30A:2170-2180.
38. Lyon CJ, Hsueh WA. 2003. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115:62S-68S.
39. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, et al. 2005. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 67:1762-1771.
40. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, et al. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346.
41. Lopez-Alemany R, Redondo JM, Nagamine Y, Munoz-Canoves P. 2003. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 270:814-821.
42. Venugopal J, Hanashiro K, Yang ZZ, Nagamine Y. 2004. Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc Natl Acad Sci USA 101:17120-17125.
43. Bajou K, Lewalle J, Martinez C, Soria C, Lu H, et al. 2002. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer 100:501-516.
44. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, et al. 2001. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 61:5587-5594.
45. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. 2001. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276:8135-8141.
46. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. 2004. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23:6986-6990.
47. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, et al. 2002. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17:56-61.
48. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. 2002. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 106:2372-2378.
49. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. 2004. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 286:H1910-1915.
50. Hewett PW, Murray C. 1996. Modulation of human endothelial cell procoagulant activity in tumour models in vitro. Int J Cancer 66:784-789.
51. Hertig A, Rondeau E. 2004. Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 15:844-853.
52. Pontrelli P, Ranieri E, Ursi M, Ghosh-Choudhury G, Gesualdo L, et al. 2004. jun-N-terminal kinase regulates thrombin-induced PAI-1 gene expression in proximal tubular epithelial cells. Kidney Int 65:2249-2261.
53. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, et al. 2004. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64:8613-8619.
54. Langer F, Amirkhosravi A, Ingersoll SB, Walker JM, Spath B, et al. 2006. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 4:1056-1062.
55. Kwaan HC, Wang J, Svoboda K, Declerck PJ. 2000. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 82:1702-1708.
56. Chen Y, Kelm RJ Jr., Budd RC, Sobel BE, Schneider DJ. 2004. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 92:178-188.
57. Hawks K, Higgins PJ. 1998. Cell shape-dependent pathway of plasminogen activator inhibitor type-1 gene expression requires cytoskeletal reorganization. J Cell Physiol 176:293-302.
58. Providence KM, Kutz SM, Higgins PJ. 1999. Perturbation of the actin cytoskeleton induces PAI-1 gene expression in cultured epithelial cells independent of substrate anchorage. Cell Motil Cytoskeleton 42:218-229.
59. Lademann U, Romer MU, Jensen PB, Hofland KF, Larsen L, et al. 2005. Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis. Eur J Cancer 41:1095-1100.
60. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, et al. 2002. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16:147-154.
61. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, et al. 2001. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276:33964-33968.
62. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, et al. 2001. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152:777-784.
63. Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, et al. 2001. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 61:5587-5594.
64. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ. 2001. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33.
65. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563-1571.
66. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380-32388.
67. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. 1997. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100:58-67.
68. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, et al. 1996. Regulation of integrin function by the urokinase receptor. Science 273:1551-1555.
69. Chapman HA, Wei Y. 2001. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 86:124-129.
70. Kjoller L. 2002. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem 383:5-19.
71. Okumura Y, Kamikubo Y, Curriden SA, Wang J, Kiwada T, et al. 2002. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem 277:9395-9404.
72. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, et al. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232:420-429.
73. Palmieri D, Lee J-W, Juliano RL, Church FC. 2002. Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells. J Biol Chem 277:40950-40957.
74. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. 2003. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160:781-791.
75. Whitley BR, Palmieri D, Twerdi C, Church FC. 2004. Expression of active plasminogen activator inhibitor-1 regulates cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 296:151-162.
76. Whitley BR, Palmieri D, Church FC. 2001. Effect of plasminogen activator inhibitor (PAI)-1 and PAI-3 in MDA-MB-435 breast cell proliferation. FASEB J 15:A251.
77. Nicholson KM, Anderson IMG. 2002. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381-395.
78. Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, et al. 2004. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem 279:6143-6151.
79. Whitley BR, Beaulieu LM, Carter JC, Church FC. 2007. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 104:470-479.
80. Nguyen DHD, Catling AD, Webb DJ, Sankovic M, Walker LA, et al. 1999. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. The Journal of Cell Biology 146:149-164.
81. Nguyen DHD, Webb DJ, Catling AD, Song Q, Dhakephalkar A, et al. 2000. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-related kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. The Journal of Biological Chemistry 275:19382-19388.
82. Praus M, Wauterickx K, Collen D, Gerard RD. 1999. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Therapy 6:227-236.
83. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. 2002. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 160:237-246.
84. Hjortland GO, Bjornland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesiand JM, Fodstad O, Engebraaten O. 2003. Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin Exp Metastasis 20:301-309.
85. Degryse B, Neels JG, Czekay R-P, Aertgeerts K, Kamikubo Y-i, Loskutoff DJ. 2004. The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1. J Biol Chem 279:22595-22604.
86. Praus M, Collen D, Gerard RD. 2002. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer 102:584-591.
87. Stefansson S, Lawrence DA, Argraves WS. 1996. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 271:8215-8220.
88. Degryse B, Sier CF, Resnati M, Conese M, Blasi F. 2001. PAI-1 inhibits urokinase-induced Chemotaxis by internalizing the urokinase receptor. FEBS Lett. 505:249-254.
89. Huuhtanen RL, Wiklund TA, Blomqvist CP, Bohling TO, Virolainen MJ, et al. 1999. A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients. Br J Cancer 81:1017-1021.
90. Santell L, Marotti K, Bartfeld NS, Baynham P, Levin EG. 1992. Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cells. Exp Cell Res 201:358-365.
91. Gogas H, Fountzilas G. 2003. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 14:667-674.
92. Denken C, Weichert W, Winzer KJ, Muller BM, Noske A, et al. 2004. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 10:5580-5586.
93. Namkoong H, Shin SM, Kim HK, Ha SA, Cho GW, et al. 2006. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 6:74.
94. Piccinini M, Mostert M, Alberto G, Ramondetti C, Novi RF, et al. 2005. Down-regulation of pyruvate dehydrogenase phosphatase in obese subjects is a defect that signals insulin resistance. Obes Res 13:678-686.
95. Garver WS, Krishnan K, Gallagos JR, Michikawa M, Francis GA, Heidenreich RA. 2002. Niemann-Pick C1 protein regulates cholesterol transport to the trans-Golgi network and plasma membrane caveolae. J Lipid Res 43:579-589.
96. Gong Y, Duvvuri M, Duncan MB, Liu J, Krise JP. 2006. Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway. J Pharmacol Exp Ther 316:242-247.
97. Sarjeant JM, Lawrie A, Kinnear C, Yablonsky S, Leung W, et al. 2003. Apolipoprotein D inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferated by preventing translocation of phosphorylated extracellular signal regulated kinase 1/2 to the nucleus. Arterioscler Thromb Vasc Biol 23:2172-2177.
98. Leung WC, Lawrie A, Demaries S, Massaeli H, Burry A, et al. 2004. Apolipoprotein D and platelet-derived growth factor-BB synergism mediates vascular smooth muscle cell migration. Circ Res 95:179-186.
99. Bartholin L, Maguer-Satta V, Hayette S, Martel S, Gadoux M, et al. 2002. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene 21:2227-2235.
100. Stehlik C, Kroismayr R, Dorfleutner A, Binder BR, Lipp J. 2004. VIGR - a novel inducible adhesion family G-protein coupled receptor in endothelial cells. FEBS Lett 569:149-155.